Approval · Notice of Compliance 21426 · 2018
TASIGNA: Notice of Compliance 21426
Issued October 16, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21426
- Date
- October 16, 2018
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New pediatric indication and new strength: 50 mg
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TASIGNA | 02481715 | Cancelled Post Market |
| TASIGNA | Not yet assigned | — |